ID

13642

Description

Ranolazine for the Prevention of Atrial Fibrillation After Electrical Cardioversion; ODM derived from: https://clinicaltrials.gov/show/NCT01349491

Link

https://clinicaltrials.gov/show/NCT01349491

Keywords

  1. 2/22/16 2/22/16 -
Uploaded on

February 22, 2016

DOI

To request one please log in.

License

Creative Commons BY 4.0

Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Atrial Fibrillation NCT01349491

Eligibility Atrial Fibrillation NCT01349491

Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
male or female with persistent atrial fibrillation, aged 21 or older
Description

atrial fibrillation; age

Data type

boolean

Alias
UMLS CUI [1]
C0004238
UMLS CUI [2]
C0001779
duration of atrial fibrillation less than one year
Description

atrial fibrillation

Data type

boolean

Alias
UMLS CUI [1]
C0004238
the patient does not have any contraindications for anticoagulation
Description

Anticoagulation contraindicated

Data type

boolean

Alias
UMLS CUI [1]
C1531588
the patient is willing to participate in the study for a total of 6 months with 3 outpatient office visits
Description

compliance

Data type

boolean

Alias
UMLS CUI [1]
C1321605
the patient has provided written informed consent during the screening visit to any test or procedure being performed, or medication being changed, for this study.
Description

informed consent

Data type

boolean

Alias
UMLS CUI [1]
C0021430
the patient has no clinically significant abnormal clinical laboratory values, which in the investigator's opinion precludes the patient from safely participating in the study.
Description

laboratory value; patient safety

Data type

boolean

Alias
UMLS CUI [1]
C0011911
UMLS CUI [2]
C1113679
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
any contraindication for anticoagulation
Description

Anticoagulation contraindicated

Data type

boolean

Alias
UMLS CUI [1]
C1531588
new york heart association class iv heart failure
Description

new york heart association class iv

Data type

boolean

Alias
UMLS CUI [1]
C1319796
currently taking anti-arrhythmic drugs
Description

anti-arrhythmic drugs

Data type

boolean

Alias
UMLS CUI [1]
C0003195
chronic kidney disease (serum creatinine less than 2.5mg/dl) or severe liver dysfunction
Description

chronic kidney disease; Liver Dysfunction

Data type

boolean

Alias
UMLS CUI [1]
C1561643
UMLS CUI [2]
C0086565
pregnancy/nursing
Description

pregnant; lactating

Data type

boolean

Alias
UMLS CUI [1]
C2828358
UMLS CUI [2]
C0549206
prolonged qt interval (>500ms)
Description

prolonged qt interval

Data type

boolean

Alias
UMLS CUI [1]
C0151878
taking other medications known to prolong the qt interval
Description

medication prolonged qt interval

Data type

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0151878
taking other medications known to affect the metabolism of ranolazine
Description

ranolazine

Data type

boolean

Alias
UMLS CUI [1]
C0073633

Similar models

Eligibility Atrial Fibrillation NCT01349491

Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
atrial fibrillation; age
Item
male or female with persistent atrial fibrillation, aged 21 or older
boolean
C0004238 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
atrial fibrillation
Item
duration of atrial fibrillation less than one year
boolean
C0004238 (UMLS CUI [1])
Anticoagulation contraindicated
Item
the patient does not have any contraindications for anticoagulation
boolean
C1531588 (UMLS CUI [1])
compliance
Item
the patient is willing to participate in the study for a total of 6 months with 3 outpatient office visits
boolean
C1321605 (UMLS CUI [1])
informed consent
Item
the patient has provided written informed consent during the screening visit to any test or procedure being performed, or medication being changed, for this study.
boolean
C0021430 (UMLS CUI [1])
laboratory value; patient safety
Item
the patient has no clinically significant abnormal clinical laboratory values, which in the investigator's opinion precludes the patient from safely participating in the study.
boolean
C0011911 (UMLS CUI [1])
C1113679 (UMLS CUI [2])
Item Group
C0680251 (UMLS CUI)
Anticoagulation contraindicated
Item
any contraindication for anticoagulation
boolean
C1531588 (UMLS CUI [1])
new york heart association class iv
Item
new york heart association class iv heart failure
boolean
C1319796 (UMLS CUI [1])
anti-arrhythmic drugs
Item
currently taking anti-arrhythmic drugs
boolean
C0003195 (UMLS CUI [1])
chronic kidney disease; Liver Dysfunction
Item
chronic kidney disease (serum creatinine less than 2.5mg/dl) or severe liver dysfunction
boolean
C1561643 (UMLS CUI [1])
C0086565 (UMLS CUI [2])
pregnant; lactating
Item
pregnancy/nursing
boolean
C2828358 (UMLS CUI [1])
C0549206 (UMLS CUI [2])
prolonged qt interval
Item
prolonged qt interval (>500ms)
boolean
C0151878 (UMLS CUI [1])
medication prolonged qt interval
Item
taking other medications known to prolong the qt interval
boolean
C0013227 (UMLS CUI [1,1])
C0151878 (UMLS CUI [1,2])
ranolazine
Item
taking other medications known to affect the metabolism of ranolazine
boolean
C0073633 (UMLS CUI [1])

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial